title: Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.
abstract: Targeting therapeutic gene expression to the skeletal muscle following intravenous (IV) administration is an attractive strategy for treating peripheral arterial disease (PAD), except that vector access to the ischemic limb could be a limiting factor. As adeno-associated virus serotype 9 (AAV-9) transduces skeletal muscle at high efficiency following systemic delivery, we employed AAV-9 vectors bearing luciferase or enhanced green fluorescent protein (eGFP) reporter genes to test the hypothesis that increased desialylation of cell-surface glycans secondary to hindlimb ischemia (HLI) might help offset the reduction in tissue perfusion that occurs in mouse models of PAD. The utility of the creatine kinase-based (CK6) promoter for restricting gene expression to the skeletal muscle was also examined by comparing it with the cytomegalovirus (CMV) promoter after systemic administration following surgically induced HLI. Despite reduced blood flow to the ischemic limbs, CK6 promoter-driven luciferase activities in the ischemic gastrocnemius (GA) muscles were ∼34-, ∼28- and ∼150-fold higher than in the fully perfused contralateral GA, heart and liver, respectively, 10 days after IV administration. Furthermore, luciferase activity from the CK6 promoter in the ischemic GA muscles was ∼twofold higher than with CMV, while in the liver CK6-driven activity was ∼42-fold lower than with CMV, demonstrating that the specificity of ischemic skeletal muscle transduction can be further improved with the muscle-specific promoters. Studies with Evans blue dye and fluorescently labeled lectins revealed that vascular permeability and desialylation of the cell-surface glycans were increased in the ischemic hindlimbs. Furthermore, AAV9/CK6/Luc vector genome copy numbers were ∼sixfold higher in the ischemic muscle compared with the non-ischemic muscle in the HLI model, whereas this trend was reversed when the same genome was packaged in the AAV-1 capsid (which binds sialylated, as opposed to desialylated glycans), further underscoring the importance of desialylation in the ischemic enhancement of transduction displayed by AAV-9. Taken together, these findings suggest two complementary mechanisms contributing to the preferential transduction of ischemic muscle by AAV-9: increased vascular permeability and desialylation. In conclusion, ischemic muscle is preferentially targeted following systemic administration of AAV-9 in a mouse model of HLI. Unmasking of the primary AAV-9 receptor as a result of ischemia may contribute importantly to this effect.
authors.affiliation: Division of Cardiovascular Medicine, Department of Medicine, University of Virginia, Charlottesville, VA 22903, USA.
authors.forename: A B
authors.initials: AB
authors.lastname: Katwal
authors.forename: P R
authors.initials: PR
authors.lastname: Konkalmatt
authors.forename: B A
authors.initials: BA
authors.lastname: Piras
authors.forename: S
authors.initials: S
authors.lastname: Hazarika
authors.forename: S S
authors.initials: SS
authors.lastname: Li
authors.forename: R
authors.initials: R
authors.lastname: John Lye
authors.forename: J M
authors.initials: JM
authors.lastname: Sanders
authors.forename: E A
authors.initials: EA
authors.lastname: Ferrante
authors.forename: Z
authors.initials: Z
authors.lastname: Yan
authors.forename: B H
authors.initials: BH
authors.lastname: Annex
authors.forename: B A
authors.initials: BA
authors.lastname: French
mesh_terms: D000818:Animals; D000229:Dependovirus / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D017930:Genes, Reporter; D015316:Genetic Therapy; D005822:Genetic Vectors; D006614:Hindlimb / Q000098:blood supply; D006801:Humans; D007511:Ischemia / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal / Q000098:blood supply* / Q000378:metabolism*; D058729:Peripheral Arterial Disease / Q000378:metabolism / Q000628:therapy*; D011134:Polysaccharides / Q000378:metabolism; D011401:Promoter Regions, Genetic; D014161:Transduction, Genetic
chemical_list: D011134:Polysaccharides
references.citation: J Virol. 1999 Oct;73(10):8549-58
references.pmid: 10482608
references.citation: Gene Ther. 2007 Nov;14(22):1605-9
references.pmid: 17898796
references.citation: Curr Opin Cardiol. 2007 Sep;22(5):458-63
references.pmid: 17762548
references.citation: Circ Res. 2007 Oct 26;101(9):948-56
references.pmid: 17823371
references.citation: Mol Ther. 2007 Feb;15(2):320-9
references.pmid: 17235310
references.citation: J Biol Chem. 2011 Apr 15;286(15):13532-40
references.pmid: 21330365
references.citation: Circulation. 2003 Oct 21;108(16):1933-8
references.pmid: 14504183
references.citation: Mol Ther. 2002 Jul;6(1):127-33
references.pmid: 12095313
references.citation: Nat Genet. 1997 Jul;16(3):270-6
references.pmid: 9207793
references.citation: Clin Transl Sci. 2010 Dec;3(6):333-6
references.pmid: 21207763
references.citation: J Transl Med. 2007 Sep 24;5:45
references.pmid: 17892583
references.citation: Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75
references.pmid: 17140820
references.citation: Magn Reson Med. 2004 Feb;51(2):304-11
references.pmid: 14755656
references.citation: J Virol. 2002 May;76(9):4559-66
references.pmid: 11932421
references.citation: Gene Ther. 2011 Jan;18(1):43-52
references.pmid: 20703310
references.citation: Int J Clin Pract. 2008 Sep;62(9):1383-90
references.pmid: 18657197
references.citation: Mol Ther. 2001 Dec;4(6):586-92
references.pmid: 11735343
references.citation: Hum Gene Ther. 2002 Jul 20;13(11):1281-91
references.pmid: 12162811
references.citation: J Control Release. 2010 Nov 20;148(1):18-24
references.pmid: 20600402
references.citation: Circulation. 2008 Jul 1;118(1):9-16
references.pmid: 18591450
references.citation: Mol Ther. 2007 Apr;15(4):764-71
references.pmid: 17299410
references.citation: Nat Biotechnol. 2001 Sep;19(9):838-42
references.pmid: 11533642
references.citation: Circulation. 2002 Apr 9;105(14):1631-4
references.pmid: 11940538
references.citation: Gene Ther. 2008 Nov;15(22):1489-99
references.pmid: 18563184
references.citation: Diabetes. 2007 Mar;56(3):656-65
references.pmid: 17327433
references.citation: Mol Ther. 2006 Jul;14(1):45-53
references.pmid: 16713360
references.citation: Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10613-7
references.pmid: 7504271
references.citation: Hum Gene Ther. 2009 Feb;20(2):159-67
references.pmid: 20377367
references.citation: J Virol. 2005 Aug;79(15):9933-44
references.pmid: 16014954
references.citation: Mol Ther. 2000 Jul;2(1):16-25
references.pmid: 10899824
references.citation: Circulation. 2008 Mar 4;117(9):1207-15
references.pmid: 18285563
references.citation: J Mol Cell Cardiol. 2001 Feb;33(2):295-305
references.pmid: 11162134
references.citation: Mol Ther. 2009 May;17(5):914-21
references.pmid: 19240689
references.citation: Nat Med. 2004 Aug;10(8):828-34
references.pmid: 15273747
references.citation: Hum Gene Ther. 1996 Nov 10;7(17):2101-12
references.pmid: 8934224
references.citation: Circulation. 2011 Oct 18;124(16):1765-73
references.pmid: 21947297
references.citation: JAMA. 2001 Sep 19;286(11):1317-24
references.pmid: 11560536